Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A2A dependent.

Article Details

Citation

Copy to clipboard

Konrad FM, Neudeck G, Vollmer I, Ngamsri KC, Thiel M, Reutershan J

Protective effects of pentoxifylline in pulmonary inflammation are adenosine receptor A2A dependent.

FASEB J. 2013 Sep;27(9):3524-35. doi: 10.1096/fj.13-228122. Epub 2013 May 22.

PubMed ID

23699177 [ View in PubMed

]

Abstract

Pentoxifylline (PTX) has been shown to exert anti-inflammatory effects in experimental acute lung injury. However, results in humans were controversial. Recent in vitro studies suggested that the adenosine receptor A2A may be required for PTX to be effective. Therefore, we studied the association between A2A and PTX in a murine model of LPS-induced pulmonary inflammation. PTX treatment (10 mg/kg) reduced cellular influx (by 40%), microvascular permeability (30%), and the release of chemotactic cytokines into the alveolar space (TNF-alpha 60%, IL-6 60%, and CXCL2/3 53%, respectively). These protective effects were abolished completely in A2A(-/-) mice and in wild-type mice that had been treated with the selective A2A antagonist (1 mg/kg), but effects were not different in mice with altered adenosine levels. In vitro transmigration assays revealed a pivotal role of the endothelium in PTX-mediated PMN migration, with a reduction of 50% (2 mM PTX). This effect was also A2A dependent. Further, oxidative burst of human PMNs was A2A-dependently reduced by 53% after PTX treatment. In summary, PTX exhibits its anti-inflammatory effects in LPS-induced lung injury through an A2A-dependent pathway. These results will help to better understand previous conflicting data on PTX in inflammation and will direct further studies to consider the predominant role of A2A.

DrugBank Data that Cites this Article

Drugs

Pentoxifylline

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Pentoxifylline	Adenosine receptor A2a	Protein	Humans	Yes	Agonist	Details